statistiche ricercatore

Nazione	#
IT - Italia	11.090
US - Stati Uniti d'America	683
SG - Singapore	223
CN - Cina	156
SE - Svezia	77
VN - Vietnam	67
BR - Brasile	57
FR - Francia	39
DE - Germania	36
IN - India	31
HK - Hong Kong	27
GB - Regno Unito	22
CA - Canada	19
NL - Olanda	19
FI - Finlandia	17
BD - Bangladesh	10
AT - Austria	9
IQ - Iraq	9
KR - Corea	9
PL - Polonia	8
AE - Emirati Arabi Uniti	7
AR - Argentina	7
IR - Iran	7
TR - Turchia	7
VE - Venezuela	6
ZA - Sudafrica	6
ID - Indonesia	5
JP - Giappone	5
PH - Filippine	5
RU - Federazione Russa	5
SA - Arabia Saudita	5
ES - Italia	4
GR - Grecia	4
IE - Irlanda	4
IL - Israele	4
PK - Pakistan	4
TH - Thailandia	4
UZ - Uzbekistan	4
AU - Australia	3
CL - Cile	3
EC - Ecuador	3
MA - Marocco	3
BH - Bahrain	2
MX - Messico	2
NG - Nigeria	2
TN - Tunisia	2
AL - Albania	1
AZ - Azerbaigian	1
BB - Barbados	1
BO - Bolivia	1
CO - Colombia	1
CR - Costa Rica	1
DZ - Algeria	1
EG - Egitto	1
HR - Croazia	1
KE - Kenya	1
KG - Kirghizistan	1
LT - Lituania	1
LU - Lussemburgo	1
MN - Mongolia	1
MO - Macao, regione amministrativa speciale della Cina	1
MY - Malesia	1
NO - Norvegia	1
OM - Oman	1
PE - Perù	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	12.745

Nome	#
Molecular-biology-driven treatment for metastatic colorectal cancer	2.771
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment	1.357
Molecular-driven treatment for biliary tract cancer: the promising turning point	1.222
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors	1.074
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?	934
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment	868
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression	786
Uncovering key targets of success for immunotherapy in pancreatic cancer	720
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus	676
The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials	646
BRCA-mutant pancreatic ductal adenocarcinoma	618
Immune Checkpoint Inhibitors in the Treatment of HCC	590
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	334
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients	199
Totale	12.795

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	172	0	0	0	0	0	0	0	0	0	70	49	53
2021/2022	1.147	53	48	3	25	40	84	56	120	69	95	188	366
2022/2023	2.498	275	375	260	167	184	233	115	157	164	292	182	94
2023/2024	1.946	79	56	80	107	166	354	365	160	97	97	186	199
2024/2025	4.934	1.486	1.641	403	463	209	319	214	26	37	51	31	54
2025/2026	1.311	130	82	105	116	96	105	342	139	96	100	0	0
Totale													12.795

UNICA IRIS Institutional Research Information System